In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors. In this short review, we seek to provide a brief yet informative survey of the 4 preeminent mechanistic approaches to pretargeting, strategies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, and bioorthogonal click chemistry.

体内预靶向是一种有前途的方法，可利用抗体的精湛的肿瘤靶向特性进行核成像和治疗，同时规避其药代动力学限制。预靶向的核心前提是分别施用靶向载体和放射性同位素，并使2种成分在体内结合。以这种方式，预靶向策略减少了放射性物质的循环时间，减少了健康非靶组织中放射性核素的吸收，并促进了寿命短的放射性核素的使用，否则这些放射性核素将与基于抗体的载体不兼容。在这篇简短的评论中，我们力求对4种出色的预靶向机制方法，基于链霉亲和素和生物素的策略，双特异性抗体，